Open Access 27-06-2025 | Correction
Correction: Quality of life among women with symptomatic, screen‑detected, and interval breast cancer, and for women without breast cancer: a retrospective cross‑sectional study from Norway
Gepubliceerd in: Quality of Life Research
Correction to: Quality of Life Research (2022) 31:1057–1068 https://doi.org/10.1007/s11136-021-03017-7
In the original publication of the article, partial information from women who refused to participate in the study was mistakenly included for comparison in Table 1, Table A3 and Results section.
Tables 1 and A3 and the text of the article related to the tables were now corrected after exclusion of this information. These changes did not affect the main results of the study.
The incorrect and corrected versions of Table 1 and Table A3 are provided in this correction. Also the sentence “Sensitivity analyses showed mean tumor diameter to be smaller and the proportion of lymph node positive tumors lower for women with symptomatic cancer included in the analyses, compared to those not included (20.3, SD: 13.1 mm versus 22.2, 16.2 mm; 27.0%, 276/1021 versus 30.8%, 455/1479, p < 0.05 for both).” in second paragraph of the Results section should have been “Sensitivity analyses showed mean tumor diameter to be smaller and the proportion of lymph node positive tumors lower for women with symptomatic cancer included in the analyses, compared to those not included (20.3, SD: 13.0 mm versus 22.1, SD: 15.5 mm; 27.0%, 276/1021 versus 31.2%, 439/1406, p < 0.05 for both).”
Incorrect table
Table 1
Baseline characteristics of women included and not included in the analyses
Variable | Women included in the analyses (n = 4487) | Women not included in the analyses (n = 7013) | ||||||
|---|---|---|---|---|---|---|---|---|
Symptomatic cancer (n = 1021) | Screen-detected cancer (n = 1206) | Interval cancer (n = 1005) | Without breast cancer (n = 1255) | Symptomatic cancer (n = 1479) | Screen-detected cancer (n = 1294) | Interval cancer (n = 1495) | Without breast cancer (n = 2745) | |
Age at recruitment Mean (SD), years | 65.2 (6.8) | 67.4 (6.3)* | 67.4 (6.0)# | 65.5 (7.4)§& | 66.3 (7.0)~ | 68.3 (6.5)*~ | 68.1 (6.3)#~ | 66.6 (8.2)§&~ |
Age at diagnosis Mean (SD), years | 57.3 (6.2) | 59.9 (5.7)* | 59.6 (5.4)# | 58.5 (6.2)~ | 60.4 (5.7)*~ | 60.0 (5.4)#~ | ||
Time since diagnosis Mean (SD), years | 8.0 (3.4) | 7.6 (3.4)* | 7.8 (3.5) | 7.8 (3.3) | 8.0 (3.4)~ | 8.1 (3.4)#¤~ | ||
Tumor diameter | ||||||||
Mean (SD), mm | 20.3 (13.0) | 17.2 (14.3)* | 21.0 (13.5)¤ | 22.2 (16.2)~ | 16.9 (13.2)* | 21.1 (13.7)¤ | ||
Missing, n | 264 | 30 | 72 | 389 | 36 | 102 | ||
Positive lymph nodes, n (%) | 276 (27.0) | 349 (28.9) | 258 (35.6)#¤ | 455 (30.8)~ | 373 (28.8) | 522 (34.9)# | ||
Missing, n | 382 | 18 | 31 | 555 | 29 | 44 | ||
Stage at diagnosis | ||||||||
I, n (%) | 393 (38.5) | 697 (57.8)* | 375 (37.3)¤ | 487 (32.9)~ | 743 (57.4)* | 569 (38.9)#¤ | ||
II, n (%) | 397 (38.9) | 283 (23.5)* | 443 (44.1)#¤ | 562 (38.0) | 287 (22.2)* | 615 (41.1)¤ | ||
III, n (%) | 149 (14.6) | 194 (16.1) | 132 (13.1) | 272 (18.4)~ | 208 (16.1) | 211 (14.1)# | ||
IV, n (%) | 28 (2.7) | 8 (0.7) | 8 (0.8) | 60 (4.1) | 17 (1.3) | 20 (1.3) | ||
Missing, n | 54 | 24 | 47 | 98 | 39 | 80 | ||
Body mass index, kg/m2, mean (SD) | 25.7 (4.4) | 26.4 (4.3)* | 25.4 (4.2)¤ | 26.0 (4.4)&§ | ||||
Missing, n | 29 | 41 | 29 | 65 | ||||
Education | ||||||||
No or primary school, n (%) | 150 (14.7) | 231 (19.2)* | 185 (18.4) | 223 (17.8) | ||||
Secondary school, n (%) | 376 (36.8) | 469 (38.9) | 350 (34.8) | 488 (38.9) | ||||
University/college, n (%) | 487 (47.7) | 493 (40.9)* | 467 (46.5) | 538 (42.9) | ||||
Missing, n | 8 | 13 | 3 | 6 | ||||
Physical activity | ||||||||
No or < 2 h a week, n (%) | 189 (18.5) | 218 (18.1) | 131 (13.0) | 166 (13.2) | ||||
2–3 h a week, n (%) | 389 (38.1) | 524 (43.5) | 429 (42.7) | 509 (40.6) | ||||
> 3 h a week, n (%) | 433 (42.4) | 449 (37.2) | 440 (43.8) | 569 (45.3) | ||||
Missing, n | 10 | 15 | 5 | 11 | ||||
Appearance and body functioning | ||||||||
Very satisfied, n (%) | 151 (14.8) | 203 (16.8) | 167 (16.6) | 235 (18.7) | ||||
Medium satisfied, n (%) | 460 (45.1) | 586 (48.6) | 505 (50.3) | 671 (53.5) | ||||
Little satisfied, n (%) | 224 (21.9) | 257 (21.3) | 205 (20.4) | 197 (15.7) | ||||
Not satisfied at all, n (%) | 170 (16.7) | 135 (11.2) | 116 (11.5) | 71 (5.7)^&§ | ||||
Missing, n | 16 | 25 | 12 | 81 | ||||
Surgery | 1004 (98.3) | 1201 (99.6) | 994 (98.9) | |||||
Breast conserving, n (%) | 524 (51.3) | 861 (71.4)* | 561 (55.8)#¤ | |||||
Mastectomy, n (%) | 480 (47.0) | 340 (28.2)* | 433 (43.1)¤ | |||||
Missing, n | – | 3 | 1 | |||||
Chemotherapy, n (%) | 550 (53.9) | 495 (41.0)* | 573 (57.0)¤ | |||||
Radiation therapy, n (%) | 815 (79.8) | 1039 (86.2)* | 829 (82.5) | |||||
Hormonal therapy, n (%) | 491 (48.1) | 523 (43.4)* | 513 (51.0)¤ | |||||
Relapse, n (%) | 105 (10.3) | 77 (6.4) | 38 (3.8) | – | ||||
General pain, n (%) | 330 (32.3) | 295 (24.5)* | 282 (28.1) | 300 (23.9)^ | ||||
Fatigue, n (%) | 435 (42.6) | 287 (32.1)* | 345 (34.3) | 111 (8.8)^&§ | ||||
Lymphedema, n (%) | 163 (16.0) | 154 (12.8) | 141 (14.0) | 14 (1.1)^&§ | ||||
Mobility, Mean (SD) | 1.5 (0.8) | 1.5 (0.8) | 1.4 (0.8)¤ | 1.3 (0.7) | ||||
Self-care, Mean (SD) | 1.1 (0.4) | 1.1 (0.3) | 1.1 (0.3) | 1.1 (0.3) | ||||
Usual activities, Mean (SD) | 1.7 (1.0) | 1.5 (0.8) | 1.6 (0.8)# | 1.3 (0.6)^&§ | ||||
Pain/discomfort, Mean (SD) | 2.2 (1.0) | 2.0 (0.8) | 2.1 (0.8) | 2.0 (0.8)^ | ||||
Anxiety/depression, Mean (SD) | 1.7 (0.8) | 1.5 (0.8) | 1.5 (0.7) | 1.4 (0.6)^ | ||||
Health utility value (0–1), Mean (SD) | 0.77 (0.16) | 0.81 (0.14)* | 0.80 (0.13)# | 0.83 (0.13)^&§ | ||||
Quality of life (0–100) | ||||||||
Median (IQR) | 60 (49–80) | 70 (50–80) | 70 (50–80) | 80 (70–90) | ||||
Incorrect table
Table A3
Available baseline characteristics for the sample before recruitment, all excluded women and women included in the study
Variable | The sample before recruitment | All excluded women | Included women | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Women with symptomatic cancer (n=2500) | Women with screen-detected cancer (n=2500) | Women with interval cancer (n=2500) | Women without breast cancer (n=4000) | Women with symptomatic cancer (n=1479) | Women with screen-detected cancer (n=1294) | Women with interval cancer (n=1495) | Women without breast cancer (n=2745) | Women with symptomatic cancer (n=1021) | Women with screen-detected cancer (n=1206) | Women with interval cancer (n=1005) | Women without breast cancer (n=1255) | |
Age at diagnosis, mean (SD), years | 58.0 (6.2) | 60.1 (5.7)* | 59.9 (5.4)# | 58.5 (6.2) | 60.4 (5.7)* | 60.0 (5.4)# | 57.3 (6.2)~ | 59.9 (5.7)*~ | 59.6 (5.4)#~ | |||
Age at recruitment, mean (SD), years | 65.9 (6.9) | 67.9 (6.5)* | 67.8 (6.2)# | 66.3 (8.0)&^§ | 66.3 (7.0) | 68.3 (6.5)* | 68.1 (6.3)# | 66.6 (8.2)&§ | 65.2 (6.8)~ | 67.4 (6.3)*~ | 67.4 (6.0)#~ | 65.5 (7.4)&§~ |
Time since diagnosis, mean (SD), years | 7.9 (3.4) | 7.8 (3.4) | 8.0 (3.4)¤ | 7.8 (3.3) | 8.0 (3.4) | 8.1 (3.4)# | 8.0 (3.4) | 7.6 (3.4)*~ | 7.8 (3.5)~ | |||
Tumor diameter, mean (SD), mm | 21.4 (15.0) | 17.1 (13.7)* | 21.1 (13.6)¤ | 22.2 (16.2) | 16.9 (13.2)* | 21.1 (13.7)¤ | 20.3 (13.0)~ | 17.2 (14.3)* | 21.0 (13.5)¤ | |||
Missing, n (%) | 653 (26.1) | 66 (2.6) | 174 (7.0) | 389 (26.3) | 36 (2.8) | 102 (6.8) | 264 (25.9) | 30 (2.5) | 72 (7.2) | |||
Positive lymph nodes, n (%) | 731 (29.2) | 722 (28.9)* | 880 (35.2)#¤ | 455 (30.8) | 373 (28.8) | 522 (24.9)# | 276 (27.0)~ | 349 (28.9) | 258 (35.6)#¤~ | |||
Missing, n (%) | 937 (37.5) | 47 (1.9) | 75 (3.0) | 555 (37.5) | 29 (2.2) | 44 (2.9) | 382 (37.4) | 18 (1.5) | 31 (3.1) | |||
Stage at diagnosis | ||||||||||||
I, n (%) | 880 (35.2) | 1440 (57.6)* | 944 (37.8)¤ | 487 (32.9) | 743 (57.4)* | 569 (38.9)#¤ | 393 (38.5)~ | 697 (57.8)* | 375 (37.3)¤ | |||
II, n (%) | 959 (38.4) | 570 (22.8)* | 1058 (42.3)¤ | 562 (38.0) | 287 (22.2)* | 615 (41.1)¤ | 397 (38.9) | 283 (23.5)* | 443 (44.1)#¤ | |||
III, n (%) | 421 (16.8) | 402 (16.1) | 343 (13.7) | 272 (18.4) | 208 (15.1) | 211 (14.1)# | 149 (14.6)~ | 194 (16.1) | 132 (13.1) | |||
IV, n (%) | 88 (3.5) | 25 (1.0) | 28 (1.1) | 60 (4.1) | 17 (1.3) | 20 (1.3) | 28 (2.7) | 8 (0.7) | 8 (0.8) | |||
Missing, n (%) | 152 (6.1) | 63 (2.5) | 127 (5.1) | 98 (6.6) | 39 (3.0) | 80 (5.4) | 54 (5.3) | 24 (2.0) | 47 (4.7) | |||
Surgery | 2418 (96.7) | 2484 (99.4)* | 2470 (98.8)# | 1414 (95.6) | 1283 (99.2)* | 1476 (98.7)¤ | 1004 (98.3)~ | 1201 (99.6) | 994 (98.9) | |||
Breast conserving surgery, n (%) | 1211 (48.4) | 1750 (70.0)* | 1367 (54.7)#¤ | 687 (46.5) | 889 (68.7)* | 806 (53.9)#¤ | 524 (51.3)~ | 861 (71.4)* | 561 (55.8)#¤ | |||
Mastectomy, n (%) | 1207 (48.3) | 734 (29.4)* | 1103 (44.1)¤ | 727 (49.2) | 394 (30.5)* | 670 (44.8)#¤ | 480 (47.0) | 340 (28.2)* | 433 (43.1)¤ | |||
Missing, n (%) | 1 (0.0) | 6 (0.2) | 5 (0.2) | 1 (0.1) | 3 (0.2) | 4 (0.3) | - | 3 (2.5) | 1 (0.0) | |||
Chemotherapy, n (%) | 516 (20.6) | 355 (14.2)* | 550 (22.2)¤ | 292 (19.7) | 170 (13.1)* | 313 (20.9)¤ | 550 (53.9)~ | 495 (41.0)*~ | 573 (57.0)¤ ~ | |||
Missing, n (%) | 1286 (51.4) | 1369 (54.8) | 1281 (51.2) | 789 (53.3) | 714 (55.2) | 751 (50.3) | ||||||
Radiation therapy, n (%) | 1770 (70.8) | 2006 (80.2)* | 1908 (76.3)# | 1027 (69.4) | 1015 (78.4)* | 1139 (76.2)# | 815 (79.8)~ | 1039 (86.2)*~ | 829 (82.5)~ | |||
Missing, n (%) | 426 (17.0) | 276 (11.0) | 310 (12.4) | 264 (17.9) | 164 (12.7) | 178 (11.9) | ||||||
Hormonal therapy, n (%) | 543 (21.7) | 490 (19.6) | 593 (23.7) | 313 (21.2) | 256 (19.8) | 362 (24.2)#¤ | 491 (48.1)~ | 523 (43.4)*~ | 513 (51.0)¤~ | |||
Missing, n (%) | 1241 (49.6) | 1266 (50.6) | 1225 (49.0) | 747 (50.5) | 654 (50.5) | 705 (47.2) | ||||||
Correct table
Table 1
Baseline characteristics of women included and not included in the analyses
Variable | Women included in the analyses (n = 4487) | Women not included in the analyses (n = 6670)£ | ||||||
|---|---|---|---|---|---|---|---|---|
Symptomatic cancer (n = 1021) | Screen-detected cancer (n = 1206) | Interval cancer (n = 1005) | Without breast cancer (n = 1255) | Symptomatic cancer (n = 1406) | Screen-detected cancer (n = 1211) | Interval cancer (n = 1427) | Without breast cancer (n = 2626) | |
Age at recruitment Mean (SD), years | 65.2 (6.8) | 67.4 (6.3)* | 67.4 (6.0)# | 65.5 (7.4)§& | 66.1 (6.9) | 68.3 (6.5)* | 67.9 (6.3)# | 66.6(8.2)§&~ |
Age at diagnosis Mean (SD), years | 57.3 (6.2) | 59.9 (5.7)* | 59.6 (5.4)# | 58.4 (6.2) | 60.4 (5.7)* | 59.9 (5.4)# | ||
Time since diagnosis Mean (SD), years | 8.0 (3.4) | 7.6 (3.4)* | 7.8 (3.5) | 7.7 (3.3) | 8.0 (3.4) | 8.1 (3.4)# | ||
Tumor diameter | ||||||||
Mean (SD), mm | 20.3 (13.0) | 17.2 (14.3)* | 21.0 (13.5)¤ | 22.1 (15.5) | 16.9 (13.2)* | 21.2 (13.8)¤ | ||
Missing, n | 264 | 30 | 72 | 356 (25.3) | 36 (3.0) | 99 (6.9) | ||
Positive lymph nodes, n (%) | 276 (27.0) | 349 (28.9) | 258 (35.6)#¤ | 439 (31.2) | 346 (28.6) | 505 (35.4)# | ||
Missing, n | 382 | 18 | 31 | 513 (36.5) | 27 (2.2) | 41 (2.9) | ||
Stage at diagnosis | ||||||||
I, n (%) | 393 (38.5) | 697 (57.8)* | 375 (37.3)¤ | 457 (32.5) | 695 (57.4)* | 537 (37.6)#¤ | ||
II, n (%) | 397 (38.9) | 283 (23.5)* | 443 (44.1)#¤ | 537 (38.5) | 272 (22.5)* | 588 (41.2)¤ | ||
III, n (%) | 149 (14.6) | 194 (16.1) | 132 (13.1) | 261 (18.6) | 190 (15.9) | 206 (14.4)# | ||
IV, n (%) | 28 (2.7) | 8 (0.7) | 8 (0.8) | 58 (4.1) | 16 (1.3) | 19 (1.3) | ||
Missing, n | 54 | 24 | 47 | 93 (6.6) | 38 (3.1) | 77 (5.4) | ||
Body mass index, kg/m2, mean (SD) | 25.7 (4.4) | 26.4 (4.3)* | 25.4 (4.2)¤ | 26.0 (4.4)&§ | ||||
Missing, n | 29 | 41 | 29 | 65 | ||||
Education | ||||||||
No or primary school, n (%) | 150 (14.7) | 231 (19.2)* | 185 (18.4) | 223 (17.8) | ||||
Secondary school, n (%) | 376 (36.8) | 469 (38.9) | 350 (34.8) | 488 (38.9) | ||||
University/college, n (%) | 487 (47.7) | 493 (40.9)* | 467 (46.5) | 538 (42.9) | ||||
Missing, n | 8 | 13 | 3 | 6 | ||||
Physical activity | ||||||||
No or < 2 h a week, n (%) | 189 (18.5) | 218 (18.1) | 131 (13.0) | 166 (13.2) | ||||
2–3 h a week, n (%) | 389 (38.1) | 524 (43.5) | 429 (42.7) | 509 (40.6) | ||||
> 3 h a week, n (%) | 433 (42.4) | 449 (37.2) | 440 (43.8) | 569 (45.3) | ||||
Missing, n | 10 | 15 | 5 | 11 | ||||
Appearance and body functioning | ||||||||
Very satisfied, n (%) | 151 (14.8) | 203 (16.8) | 167 (16.6) | 235 (18.7) | ||||
Medium satisfied, n (%) | 460 (45.1) | 586 (48.6) | 505 (50.3) | 671 (53.5) | ||||
Little satisfied, n (%) | 224 (21.9) | 257 (21.3) | 205 (20.4) | 197 (15.7) | ||||
Not satisfied at all, n (%) | 170 (16.7) | 135 (11.2) | 116 (11.5) | 71 (5.7)^&§ | ||||
Missing, n | 16 | 25 | 12 | 81 | ||||
Surgery | 1004 (98.3) | 1201 (99.6) | 994 (98.9) | |||||
Breast conserving, n (%) | 524 (51.3) | 861 (71.4)* | 561 (55.8)#¤ | |||||
Mastectomy, n (%) | 480 (47.0) | 340 (28.2)* | 433 (43.1)¤ | |||||
Missing, n | – | 3 | 1 | |||||
Chemotherapy, n (%) | 550 (53.9) | 495 (41.0)* | 573 (57.0)¤ | |||||
Radiation therapy, n (%) | 815 (79.8) | 1039 (86.2)* | 829 (82.5) | |||||
Hormonal therapy, n (%) | 491 (48.1) | 523 (43.4)* | 513 (51.0)¤ | |||||
Relapse, n (%) | 105 (10.3) | 77 (6.4) | 38 (3.8) | – | ||||
General pain, n (%) | 330 (32.3) | 295 (24.5)* | 282 (28.1) | 300 (23.9)^ | ||||
Fatigue, n (%) | 435 (42.6) | 287 (32.1)* | 345 (34.3) | 111 (8.8)^&§ | ||||
Lymphedema, n (%) | 163 (16.0) | 154 (12.8) | 141 (14.0) | 14 (1.1)^&§ | ||||
Mobility, Mean (SD) | 1.5 (0.8) | 1.5 (0.8) | 1.4 (0.8)¤ | 1.3 (0.7) | ||||
Self-care, Mean (SD) | 1.1 (0.4) | 1.1 (0.3) | 1.1 (0.3) | 1.1 (0.3) | ||||
Usual activities, Mean (SD) | 1.7 (1.0) | 1.5 (0.8) | 1.6 (0.8)# | 1.3 (0.6)^&§ | ||||
Pain/discomfort, Mean (SD) | 2.2 (1.0) | 2.0 (0.8) | 2.1 (0.8) | 2.0 (0.8)^ | ||||
Anxiety/depression, Mean (SD) | 1.7 (0.8) | 1.5 (0.8) | 1.5 (0.7) | 1.4 (0.6)^ | ||||
Health utility value (0–1), Mean (SD) | 0.77 (0.16) | 0.81 (0.14)* | 0.80 (0.13)# | 0.83 (0.13)^&§ | ||||
Quality of life (0–100) | ||||||||
Median (IQR) | 60 (49–80) | 70 (50–80) | 70 (50–80) | 80 (70–90) | ||||
Correct table
Table A3
Available baseline characteristics for the sample before recruitment, excluded women and women included in the study
Variable | The sample before recruitment £ | Excluded women £ | Included women | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Women with symptomatic cancer (n=2427) | Women with screen-detected cancer (n=2417) | Women with interval cancer (n=2432) | Women without breast cancer (n=3881) | Women with symptomatic cancer (n=1406) | Women with screen-detected cancer (n=1211) | Women with interval cancer (n=1427) | Women without breast cancer (n=2626) | Women with symptomatic cancer (n=1021) | Women with screen-detected cancer (n=1206) | Women with interval cancer (n=1005) | Women without breast cancer (n=1255) | |
Age at diagnosis, mean (SD), years | 57.9 (6.2) | 60.0 (5.7)* | 59.8 (5.4)# | 58.4 (6.2) | 60.4 (5.7)* | 59.9 (5.4)# | 57.3 (6.2)~ | 59.9 (5.7)*~ | 59.6 (5.4)#~ | |||
Age at recruitment, mean (SD), years | 65.7 (6.9) | 67.8 (6.5)* | 67.7 (6.2)# | 66.3 (8.0)&^§ | 66.1 (6.9) | 68.3 (6.5)* | 67.9 (6.3)# | 66.6 (8.2)&§ | 65.2 (6.8)~ | 67.4 (6.3)*~ | 67.4 (6.0)#~ | 65.5 (7.4)&§~ |
Time since diagnosis, mean (SD), years | 7.8 (3.4) | 7.7 (3.4) | 8.0 (3.4)¤ | 7.7 (3.3) | 8.0 (3.4) | 8.1 (3.4)# | 8.0 (3.4) | 7.6 (3.4)*~ | 7.8 (3.5)~ | |||
Tumor diameter, mean (SD), mm | 21.3 (14.5) | 17.1 (13.8)* | 21.1 (13.7)¤ | 22.1 (15.5) | 16.9 (13.2)* | 21.2 (13.8)¤ | 20.3 (13.0)~ | 17.2 (14.3)* | 21.0 (13.5)¤ | |||
Missing, n (%) | 620 (25.6) | 66 (2.7) | 171 (7.0) | 356 (25.3) | 36 (3.0) | 99 (6.9) | 264 (25.9) | 30 (2.5) | 72 (7.2) | |||
Positive lymph nodes, n (%) | 695 (28.8) | 715 (29.5)* | 863 (35.5)#¤ | 439 (31.2) | 346 (28.6) | 505 (35.4)# | 276 (27.0)~ | 349 (28.9) | 258 (35.6)#¤~ | |||
Missing, n (%) | 895 (36.9) | 45 (1.9) | 72 (3.0) | 513 (36.5) | 27 (2.2) | 41 (2.9) | 382 (37.4) | 18 (1.5) | 31 (3.1) | |||
Stage at diagnosis | ||||||||||||
I, n (%) | 850 (37.3) | 1392 (59.1)* | 912 (39.5)¤ | 457 (32.5) | 695 (57.4)* | 537 (37.6)#¤ | 393 (38.5)~ | 697 (57.8)* | 375 (37.3)¤ | |||
II, n (%) | 934 (41.0) | 555 (23.6)* | 1031 (44.7)¤ | 537 (38.5) | 272 (22.5)* | 588 (41.2)¤ | 397 (38.9) | 283 (23.5)* | 443 (44.1)#¤ | |||
III, n (%) | 410 (18.0) | 384 (16.3) | 338 (14.6) | 261 (18.6) | 190 (15.9) | 206 (14.4)# | 149 (14.6)~ | 194 (16.1) | 132 (13.1) | |||
IV, n (%) | 86 (3.8) | 24 (1.0) | 27 (1.2) | 58 (4.1) | 16 (1.3) | 19 (1.3) | 28 (2.7) | 8 (0.7) | 8 (0.8) | |||
Missing, n (%) | 147 (6.1) | 62 (2.6) | 124 (5.1) | 93 (6.6) | 38 (3.1) | 77 (5.4) | 54 (5.3) | 24 (2.0) | 47 (4.7) | |||
Surgery | 2348 (96.7) | 2401 (99.4)* | 2402 (98.8)# | 1344 (95.6) | 1200 (99.1)* | 1408 (98.7)¤ | 1004 (98.3)~ | 1201 (99.6) | 994 (98.9) | |||
Breast conserving surgery, n (%) | 1178 (48.5) | 1700 (70.3)* | 1331 (54.7)#¤ | 654 (46.5) | 839 (69.3)* | 770 (54.0)#¤ | 524 (51.3)~ | 861 (71.4)* | 561 (55.8)#¤ | |||
Mastectomy, n (%) | 1170 (48.2) | 701 (29.0)* | 1071 (44.0)¤ | 690 (49.0) | 361 (29.8)* | 638 (44.7)#¤ | 480 (47.0) | 340 (28.2)* | 433 (43.1)¤ | |||
Missing, n (%) | 1 (0.0) | 6 (0.2) | 5 (0.2) | 1 (0.1) | 3 (0.3) | 4 (0.3) | - | 3 (2.5) | 1 (0.0) | |||
Chemotherapy, n (%) | 505 (20.8) | 341 (14.1)* | 539 (22.2)¤ | 281 (20.0) | 156 (12.9)* | 302 (21.2)¤ | 550 (53.9)~ | 495 (41.0)*~ | 573 (57.0)¤ ~ | |||
Missing, n (%) | 1252 (51.5) | 1327 (54.9) | 1249 (51.4) | 755 (53.6) | 678 (56.0) | 720 (50.5) | ||||||
Radiation therapy, n (%) | 1722 (71.0) | 1940 (80.3)* | 1866 (76.7)# | 979 (69.6) | 949 (78.4)* | 1097 (76.9)# | 815 (79.8)~ | 1039 (86.2)*~ | 829 (82.5)~ | |||
Missing, n (%) | 418 (17.2) | 267 (11.1) | 301 (12.4) | 256 (18.2) | 155 (12.6) | 169 (11.9) | ||||||
Hormonal therapy, n (%) | 516 (21.3) | 467 (19.3) | 579 (23.8) | 286 (20.3) | 233 (19.3) | 348 (24.4)#¤ | 491 (48.1)~ | 523 (43.4)*~ | 513 (51.0)¤~ | |||
Missing, n (%) | 1214 (50.1) | 1232 (51.0) | 1201 (49.4) | 721 (51.3) | 620 (51.2) | 681 (47.7) | ||||||
The original article has been corrected.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.